Cargando…

Dynamic Changes in Non-Invasive Markers of Liver Fibrosis Are Predictors of Liver Events after SVR in HCV Patients

Objectives: The course of progressive liver damage after achieving sustained virological response (SVR) with direct-acting antivirals (DAAs) remains undetermined. We aimed to determine risk factors associated with the development of liver-related events (LREs) after SVR, focusing on the utility of n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fernández-Alvarez, Paula, Guerra-Veloz, María Fernanda, Vilches-Arenas, Angel, Cordero-Ruíz, Patricia, Bellido-Muñoz, Francisco, Caunedo-Alvarez, Angel, Carmona-Soria, Isabel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302896/ https://www.ncbi.nlm.nih.gov/pubmed/37376551 http://dx.doi.org/10.3390/v15061251

Ejemplares similares

Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease
por: Guerra Veloz, María Fernanda, et al.
Publicado: (2018)

Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data
por: Guerra Veloz, María Fernanda, et al.
Publicado: (2019)

Prevalence and predictors of abnormal alanine aminotransferase in patients with HCV who have achieved SVR
por: Chadha, Nikita, et al.
Publicado: (2022)

Influence of Genetic Variants on Disease Regression and Outcomes in HCV-Related Advanced Chronic Liver Disease after SVR
por: Semmler, Georg, et al.
Publicado: (2021)

Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results
por: Argüelles-Arias, Federico, et al.
Publicado: (2017)

Endoscopic ultrasound-guided portal pressure gradient measurement: improving safety and overcoming technical difficulties
por: Romero-Castro, Rafael, et al.
Publicado: (2023)

1069. Loss to follow-up does not impact SVR for HCV infection
por: Kottilil, Sita K, et al.
Publicado: (2020)

Characteristics and Survival Outcomes of Hepatocellular Carcinoma Developed after HCV SVR
por: Yeh, Ming-Lun, et al.
Publicado: (2021)

Anatomic and hemodynamic findings during endoscopic ultrasound-guided angiography of gastric varices: a note of caution for endoscopic ultrasound-guided therapy
por: Romero-Castro, Rafael, et al.
Publicado: (2022)

Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR
por: Vigón, Lorena, et al.
Publicado: (2019)

2896. Reduction in Liver-related Mortality Among HCV Infected Persons Is Driven by Attainment of SVR Independent of the Regimen Used: Results from the ERCHIVES Cohort
por: Butt, Adeel A, et al.
Publicado: (2019)

Concordance of SVR12, SVR24 and SVR durability in Taiwanese chronic hepatitis C patients with direct-acting antivirals
por: Lin, Chuan-Pin, et al.
Publicado: (2021)

Effect of HIV infection-related factors on SVR rate in HCV treatment in HIV-infected patients
por: Kravchenko, Alexey, et al.
Publicado: (2014)

Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months
por: Argüelles-Arias, F., et al.
Publicado: (2017)

Molecular Mechanisms of Liver Fibrosis in HIV/HCV Coinfection
por: Mastroianni, Claudio M., et al.
Publicado: (2014)

Effects of Achieving SVR on Clinical Characteristics and Surgical Outcomes in Patients Who Developed Early-Stage HCV-Related Hepatocellular Carcinoma and Received Curative Resection: Preoperative versus Postoperative SVR
por: Hsu, Po-Yao, et al.
Publicado: (2022)

SVR Rates of HCV-infected population under PEG-IFN-α/R treatment in Northwest China
por: Li, Yanhua, et al.
Publicado: (2017)

HCV Integrated Care: A Randomized Trial to Increase Treatment Initiation and SVR with Direct Acting Antivirals
por: Groessl, Erik J., et al.
Publicado: (2017)

Quadruple Therapy Offers High SVR Rates in Patients with HCV Genotype 4 with Previous Treatment Failure
por: Abo-amer, Yousry Esam-Eldin, et al.
Publicado: (2020)

Dynamics of APRI and FIB-4 in HCV cirrhotic patients who achieved SVR after DAA therapy
por: Leuştean, Anca, et al.
Publicado: (2021)

Serum Markers of Epithelial Mesenchymal Transition as Predictors of HCV-induced Liver Fibrosis, Cirrhosis and Hepatocellular Carcinoma
por: Zoheiry, Mona M, et al.
Publicado: (2015)

Noninvasive Methods to Evaluate Liver Fibrosis in Chronic HCV Infection
por: El-Shabrawi, Mortada Hassan, et al.
Publicado: (2011)

Endothelial Dysfunction Correlates with Liver Fibrosis in Chronic HCV Infection
por: Barone, Michele, et al.
Publicado: (2015)

1060. Evaluation of ALT at Sustained Virologic Response (SVR) in Patients with Treated Hepatitis C Virus (HCV) Infection
por: Theppote, Amanda, et al.
Publicado: (2020)

Prediction of liver stiffness by serum indexes in HCV-infected patients with or without HIV coinfection
por: Merchante, Nicolás, et al.
Publicado: (2021)

Circulating miRNAs as Predictor Markers for Activation of Hepatic Stellate Cells and Progression of HCV-Induced Liver Fibrosis
por: El-Ahwany, Eman, et al.
Publicado: (2016)

Risk of liver decompensation assessed in HIV/HCV co-infected individuals with advanced liver fibrosis: a faster countdown experience
por: Pedro Alves, Joao, et al.
Publicado: (2014)

Association of Periodontal Diseases and Liver Fibrosis in Patients With HCV and/or HBV infection
por: Nagao, Yumiko, et al.
Publicado: (2014)

The effects of Maraviroc on liver fibrosis in HIV/HCV co-infected patients
por: Ortega Gonzalez, Enrique, et al.
Publicado: (2014)

Platelet indices significantly correlate with liver fibrosis in HCV-infected patients
por: Shao, Lin-Nan, et al.
Publicado: (2020)

Liver Enzyme Alterations in HCV-Monoinfected and HCV/HIV-Coinfected Patients
por: Langohr, Klaus, et al.
Publicado: (2008)

Feasibility of Telaprevir-Based Triple Therapy in Liver Transplant Patients with Hepatitis C Virus: SVR 24 Results
por: Werner, Christoph R., et al.
Publicado: (2013)

Real-time liver tracking algorithm based on LSTM and SVR networks for use in surface-guided radiation therapy
por: Wang, Guangyu, et al.
Publicado: (2021)

Analysis of Effect of Antiviral Therapy on Regression of Liver Fibrosis in Patient with HCV Infection
por: Vukobrat-Bijedic, Zora, et al.
Publicado: (2014)

Evaluating Liver Fibrosis by Transient Elastometry in Patients With HIV-HCV Coinfection and Monoinfection
por: Brescini, Lucia, et al.
Publicado: (2014)

HIV-1 Tropism and Liver Fibrosis in HIV–HCV Co-Infected Patients
por: Abravanel, Florence, et al.
Publicado: (2012)

Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna
por: Steiner, Sebastian, et al.
Publicado: (2017)

Management of patients with pre-therapeutic advanced liver fibrosis following HCV eradication
por: Nahon, Pierre, et al.
Publicado: (2019)

Long-Term Impact of Direct-Acting Antivirals on Liver Fibrosis and Survival in HCV-Infected Liver Transplant Recipients
por: Gambato, Martina, et al.
Publicado: (2023)

SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience
por: Mangia, Alessandra, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_v77aa2ufdr15e98e1962ujqn3h